Top

Published in:

01-02-2013 | Original Communication

Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease

Authors: Leo H. Wang, Robert C. Bucelli, Erica Patrick, Dhanashree Rajderkar, Enrique Alvarez III, Miranda M. Lim, Gabriela DeBruin, Victoria Sharma, Sonika Dahiya, Robert E. Schmidt, Tammie S. Benzinger, Beth A. Ward, Beau M. Ances

Published in: Journal of Neurology | Issue 2/2013

Abstract

Sporadic Creutzfeldt-Jakob disease (sCJD) is a rapidly progressive dementia (RPD) that can be difficult to identify antemortem, with definitive diagnosis requiring tissue confirmation. We describe the clinical, magnetic resonance imaging (MRI), cerebrospinal fluid (CSF), and electroencephalogram (EEG) measures of a small cohort of 30 patients evaluated for RPD. Clinical and diagnostic measures were cross-sectionally obtained from 17 sCJD patients (15 definite, two probable), 13 non-prion rapidly progressive dementia patients (npRPD), and 18 unimpaired controls. In a subset of patients (nine sCJD and nine npRPD) diffusion tensor imaging (DTI) measures [fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD)] were also obtained for the caudate, corpus callosum, posterior limb of the internal capsule, pulvinar, precuneus, and frontal lobe. Differences among groups were assessed by an analysis of variance. Compared to npRPD individuals, sCJD patients had cerebellar dysfunction, significantly higher CSF tau, “positive” CSF 14-3-3, and hyperintensities on diffusion-weighted imaging (DWI) that met previously established imaging criteria for sCJD. EEG changes were similar for the two groups. In addition, sCJD patients had significant decreases in DTI measures (MD, AD, RD but not FA) within the caudate and pulvinar compared to either npRPD patients or unimpaired controls. Our results confirm that CSF abnormalities and MRI (especially DWI) can assist in distinguishing sCJD patients from npRPD patients. Future longitudinal studies using multiple measures (including CSF and MRI) are needed for evaluating pathological changes seen in sCJD patients.

Available only for authorised users

Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N, Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H (1999) Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46(2):224–233PubMedCrossRef

Kovacs GG, Puopolo M, Ladogana A, Pocchiari M, Budka H, van Duijn C, Collins SJ, Boyd A, Giulivi A, Coulthart M, Delasnerie-Laupretre N, Brandel JP, Zerr I, Kretzschmar HA, de Pedro-Cuesta J, Calero-Lara M, Glatzel M, Aguzzi A, Bishop M, Knight R, Belay G, Will R, Mitrova E (2005) Genetic prion disease: the EUROCJD experience. Hum Genet 118(2):166–174PubMedCrossRef

Geschwind MD, Shu H, Haman A, Sejvar JJ, Miller BL (2008) Rapidly progressive dementia. Ann Neurol 64(1):97–108. doi:10.1002/ana.21430 PubMedCrossRef

World OH (1998) Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: report of a WHO consultation, 1 Sept 2010

Collins SJ, Sanchez-Juan P, Masters CL, Klug GM, van Duijn C, Poleggi A, Pocchiari M, Almonti S, Cuadrado-Corrales N, de Pedro-Cuesta J, Budka H, Gelpi E, Glatzel M, Tolnay M, Hewer E, Zerr I, Heinemann U, Kretszchmar HA, Jansen GH, Olsen E, Mitrova E, Alperovitch A, Brandel JP, Mackenzie J, Murray K, Will RG (2006) Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 129(Pt 9):2278–2287PubMedCrossRef

Vitali P, Maccagnano E, Caverzasi E, Henry RG, Haman A, Torres-Chae C, Johnson DY, Miller BL, Geschwind MD (2011) Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology 76(20):1711–1719PubMedCrossRef

Young GS, Geschwind MD, Fischbein NJ, Martindale JL, Henry RG, Liu S, Lu Y, Wong S, Liu H, Miller BL, Dillon WP (2005) Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol 26(6):1551–1562PubMed

Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, Breithaupt M, Varges D, Meissner B, Ladogana A, Schuur M, Haik S, Collins SJ, Jansen GH, Stokin GB, Pimentel J, Hewer E, Collie D, Smith P, Roberts H, Brandel JP, van Duijn C, Pocchiari M, Begue C, Cras P, Will RG, Sanchez-Juan P (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 132(Pt 10):2659–2668PubMedCrossRef

Perry DC, Geschwind MD (2011) Prion disease: thorough work-up and new diagnostic criteria needed for CJD. Nat Rev Neurol 7(9):479–480PubMedCrossRef

10.

Yamada K, Sakai K, Akazawa K, Yuen S, Nishimura T (2009) MR tractography: a review of its clinical applications. Magn Reson Med Sci 8(4):165–174PubMedCrossRef

11.

Naismith RT, Xu J, Tutlam NT, Scully PT, Trinkaus K, Snyder AZ, Song SK, Cross AH (2010) Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole. Neurology 74(21):1694–1701PubMedCrossRef

12.

Geschwind MD, Haman A, Miller BL (2007) Rapidly progressive dementia. Neurol Clin 25(3):783–807PubMedCrossRef

13.

Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J, McKee A, Brandel JP, Chaudhuri KR, Lai EC, D’Olhaberriague L, Pearce RK, Agid Y (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 55(7):969–978PubMedCrossRef

14.

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12):1863–1872PubMedCrossRef

15.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944PubMedCrossRef

16.

Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schulz-Schaeffer W, Kretzschmar HA, Poser S (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58(2):192–197PubMedCrossRef

17.

Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, Farlow M, Dickson DW, Sima AA, Trojanowski JQ, Petersen RB, Gambetti P (1996) Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 39(6):767–778PubMedCrossRef

18.

Castellani RJ, Colucci M, Xie Z, Zou W, Li C, Parchi P, Capellari S, Pastore M, Rahbar MH, Chen SG, Gambetti P (2004) Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology 63(3):436–442PubMedCrossRef

19.

Steinhoff BJ, Zerr I, Glatting M, Schulz-Schaeffer W, Poser S, Kretzschmar HA (2004) Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol 56(5):702–708PubMedCrossRef

20.

Shimony JS, Sheline YI, D’Angelo G, Epstein AA, Benzinger TL, Mintun MA, McKinstry RC, Snyder AZ (2009) Diffuse microstructural abnormalities of normal-appearing white matter in late life depression: a diffusion tensor imaging study. Biol Psychiatry 66(3):245–252PubMedCrossRef

21.

Klug GM, Wand H, Boyd A, Law M, Whyte S, Kaldor J, Masters CL, Collins S (2009) Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease cluster. Brain 132(Pt 2):493–501PubMed

22.

Gambetti P, Dong Z, Yuan J, Xiao X, Zheng M, Alshekhlee A, Castellani R, Cohen M, Barria MA, Gonzalez-Romero D, Belay ED, Schonberger LB, Marder K, Harris C, Burke JR, Montine T, Wisniewski T, Dickson DW, Soto C, Hulette CM, Mastrianni JA, Kong Q, Zou WQ (2008) A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol 63(6):697–708PubMedCrossRef

23.

Gambetti P, Kong Q, Zou W, Parchi P, Chen SG (2003) Sporadic and familial CJD: classification and characterisation. Br Med Bull 66:213–239PubMedCrossRef

24.

Binelli S, Agazzi P, Canafoglia L, Scaioli V, Panzica F, Visani E, Di Fede G, Giaccone G, Bizzi A, Bugiani O, Avanzini G, Tagliavini F, Franceschetti S (2010) Myoclonus in Creutzfeldt-Jakob disease: polygraphic and video-electroencephalography assessment of 109 patients. Mov Disord Off J Mov Disord Soc 25(16):2818–2827CrossRef

25.

Cohen OS, Prohovnik I, Korczyn AD, Ephraty L, Nitsan Z, Tsabari R, Appel S, Rosenmann H, Kahana E, Chapman J (2011) The Creutzfeldt-Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression. Acta Neurol Scand 124(6):368–374PubMedCrossRef

26.

Cohen OS, Hoffmann C, Lee H, Chapman J, Fulbright RK, Prohovnik I (2009) MRI detection of the cerebellar syndrome in Creutzfeldt-Jakob disease. Cerebellum 8(3):373–381PubMedCrossRef

27.

Chohan G, Pennington C, Mackenzie JM, Andrews M, Everington D, Will RG, Knight RS, Green AJ (2010) The role of cerebrospinal fluid 14–3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry 81(11):1243–1248PubMedCrossRef

28.

Kantarci K, Avula R, Senjem ML, Samikoglu AR, Zhang B, Weigand SD, Przybelski SA, Edmonson HA, Vemuri P, Knopman DS, Ferman TJ, Boeve BF, Petersen RC, Jack CR Jr (2010) Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI. Neurology 74(22):1814–1821PubMedCrossRef

29.

Sexton CE, Kalu UG, Filippini N, Mackay CE, Ebmeier KP (2010) A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging. 32(12):2322.e5–18

30.

Haik S, Dormont D, Faucheux BA, Marsault C, Hauw JJ (2002) Prion protein deposits match magnetic resonance imaging signal abnormalities in Creutzfeldt-Jakob disease. Ann Neurol 51(6):797–799PubMedCrossRef

31.

Mittal S, Farmer P, Kalina P, Kingsley PB, Halperin J (2002) Correlation of diffusion-weighted magnetic resonance imaging with neuropathology in Creutzfeldt-Jakob disease. Arch Neurol 59(1):128–134PubMedCrossRef

32.

Manners DN, Parchi P, Tonon C, Capellari S, Strammiello R, Testa C, Tani G, Malucelli E, Spagnolo C, Cortelli P, Montagna P, Lodi R, Barbiroli B (2009) Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease. Neurology 72(16):1425–1431PubMedCrossRef

33.

Geschwind MD, Potter CA, Sattavat M, Garcia PA, Rosen HJ, Miller BL, DeArmond SJ (2009) Correlating DWI MRI with pathologic and other features of Jakob-Creutzfeldt disease. Alzheimer Dis Assoc Disord 23(1):82–87PubMedCrossRef

34.

Armstrong RA, Lantos PL, Cairns NJ (2002) Spatial patterns of the vacuolation in subcortical white matter in sporadic Creutzfeldt-Jakob disease (sCJD). Clin Neuropathol 21(6):284–288PubMed

35.

Liberski PP, Sikorska B, Hauw JJ, Kopp N, Streichenberger N, Giraud P, Boellaard J, Budka H, Kovacs GG, Ironside J, Brown P (2010) Ultrastructural characteristics (or evaluation) of Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies or prion diseases. Ultrastruct Pathol 34(6):351–361PubMedCrossRef

36.

Liberski PP, Streichenberger N, Giraud P, Soutrenon M, Meyronnet D, Sikorska B, Kopp N (2005) Ultrastructural pathology of prion diseases revisited: brain biopsy studies. Neuropathol Appl Neurobiol 31(1):88–96PubMedCrossRef

37.

Sotak CH (2002) The role of diffusion tensor imaging in the evaluation of ischemic brain injury: a review. NMR Biomed 15(7–8):561–569PubMedCrossRef

38.

Mohammadi S, Nagy Z, Moller HE, Symms MR, Carmichael DW, Josephs O, Weiskopf N (2012) The effect of local perturbation fields on human DTI: characterisation, measurement and correction. NeuroImage 60(1):562–570PubMedCrossRef

39.

Atarashi R, Satoh K, Sano K, Fuse T, Yamaguchi N, Ishibashi D, Matsubara T, Nakagaki T, Yamanaka H, Shirabe S, Yamada M, Mizusawa H, Kitamoto T, Klug G, McGlade A, Collins SJ, Nishida N (2011) Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 17(2):175–178PubMedCrossRef

40.

Edgeworth JA, Farmer M, Sicilia A, Tavares P, Beck J, Campbell T, Lowe J, Mead S, Rudge P, Collinge J, Jackson GS (2011) Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 377(9764):487–493PubMedCrossRef

Title: Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease
Authors: Leo H. Wang
Robert C. Bucelli
Erica Patrick
Dhanashree Rajderkar
Enrique Alvarez III
Miranda M. Lim
Gabriela DeBruin
Victoria Sharma
Sonika Dahiya
Robert E. Schmidt
Tammie S. Benzinger
Beth A. Ward
Beau M. Ances
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 2/2013
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-012-6664-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Generalized tonic–clonic seizures and antiepileptic drugs during pregnancy—a matter of importance for the baby?

Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections

Supporting evidence for using biomarkers in the diagnosis of MCI due to AD

Clinical evolution of seizures: distribution across time of day and sleep/wakefulness cycle

Characterization of cognitive and motor performance during dual-tasking in healthy older adults and patients with Parkinson’s disease

Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson’s disease